Remarkable and sustained remission of an anaplastic thyroid carcinoma patient to the combined treatment of multimodal radiotherapy, anlotinib and toripalimab

Yurou Xingxin wu^*

• West China Hospital, Sichuan University, Chengdu, China

Anaplastic thyroid carcinoma (ATC) is an extremely aggressive thyroid tumor that accounts for approximately 1-2% of all thyroid cancers(1). ATC is most common in older adults and women(2, 3). ATC often manifests as a mass in the neck, and symptoms, such as hoarseness, difficulty swallowing, difficulty breathing, etc(4). Imaging examinations of ATCs include cervical ultrasound, CT and positron emission tomography (PET)-CT. The methods used to obtain pathological tissue include fine needle puncture, surgical biopsy, etc. ATC has a high probability of adjacent tissue invasion and metastasis, with the main type of metastasis usually occurring in the lungs, followed by bone(1). ATC has a high fatality rate, the median survival time is only 3- 6 months, and the one-year overall survival (OS) rate is approximately 20%(5). However, there is no optimal treatment standard for ATC patients. Traditional treatment modalities include surgery, radiotherapy, and chemotherapy (6), but the therapeutic effect is limited. Targeted therapy for driver gene mutation and immunotherapy are new therapeutic options(7, 8). We report that in an advanced ATC patient who received multimodal radiotherapy, anlotinib (an antiangiogenic drug) and toripalimab (a PD-1 antibody), the tumors were effectively controlled for more than two years......